Garivulimab

Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity.
Read more
€0.00 (tax incl.)
Reference:
HY-P99633
Product Details
HY-P99633

Data sheet

Size
Multiple sizes
Reactivity
PD-1/PD-L1; Apoptosis
Application
Cancer-programmed cell death
CAS
2342597-81-1

Menu

Settings